Drug interactions
Atenolol-chlorthalidone + Dihydroergotamine intranasal
Severity: Moderate
Atenolol-chlorthalidone and Dihydroergotamine intranasal: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Intranasal dihydroergotamine can cause vasoconstriction, and beta-blockade may leave it unopposed, reducing peripheral blood flow. Systemic exposure is lower than with injection but clinically relevant.
What this interaction means in plain words
Atenolol-chlorthalidone and Dihydroergotamine intranasal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Beta-blockade removes peripheral vasodilation, allowing ergot-induced vasoconstriction to dominate.
What to do
Monitor for signs of peripheral ischemia such as cold, painful or numb extremities, and discontinue dihydroergotamine if they occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Atenolol-chlorthalidone and Dihydroergotamine intranasal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Atenolol-chlorthalidone
Frequently asked questions
Can I take Atenolol-chlorthalidone with Dihydroergotamine intranasal?
MediHelp rates the interaction as moderate. Atenolol-chlorthalidone and Dihydroergotamine intranasal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Intranasal dihydroergotamine can cause vasoconstriction, and beta-blockade may leave it unopposed, reducing peripheral blood flow. Systemic exposure is lower than with injection but clinically relevant.
How serious is the interaction between Atenolol-chlorthalidone and Dihydroergotamine intranasal?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for signs of peripheral ischemia such as cold, painful or numb extremities, and discontinue dihydroergotamine if they occur.
What other medicines interact with Atenolol-chlorthalidone?
MediHelp also lists interactions of Atenolol-chlorthalidone with, for example, Acebutolol, Aldesleukin, Amiodarone. The full list is on the Atenolol-chlorthalidone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
